University ofTours, Tours, France

Laboratoire Biophysique Médicale et pharmaceutique

[Group description | Scientific staff | Publications within DiMI]

References

Radiopharmaceutical development

 

  1. Chalon S, Tarkiainen J, Garreau L, Hall H, Emond P, Vercouillie J, Farde L, Dasse P, Varnas K, Besnard JC, Halldin C, Guilloteau D. Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenylthio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity. J Pharmacol Exp Ther. 2003 Jan;304(1):81-7.
  2. Emond P, Vercouillie J, Innis R, Chalon S, Mavel S, Frangin Y, Halldin C, Besnard JC, Guilloteau D. Substituted diphenyl sulfides as selective
    serotonin transporter ligands: synthesis and in vitro evaluation. J Med Chem. 2002 Mar 14;45(6):1253-8.
  3. Emond P, Helfenbein J, Chalon S, Garreau L, Vercouillie J, Frangin Y, Besnard JC, Guilloteau D. Synthesis of tropane and nortropane
    analogues with phenyl substitutions as serotonin transporter ligands. Bioorg Med Chem. 2001 Jul;9(7):1849-55.
  4. Chalon S, Garreau L, Emond P, Zimmer L, Vilar MP, Besnard JC, Guilloteau D.Pharmacological characterization of (E)-N-(3-iodoprop-2-
    enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J
    Pharmacol Exp Ther. 1999 Nov;291(2):648-54.
  5. Hall H, Halldin C, Guilloteau D, Chalon S, Emond P, Besnard J, Farde L, Sedvall G. Visualization of the dopamine transporter in the human
    brain postmortem with the new selective ligand [125I]PE2I. Neuroimage. 1999 Jan;9(1):108-16.
  6. Helfenbein J, Sandell J, Halldin C, Chalon S, Emond P, Okubo Y, Chou YH, Frangin Y, Douziech L, Gareau L, Swahn CG, Besnard JC, Farde
    L, Guilloteau D. PET examination of three potent cocaine derivatives as specific radioligands for the serotonin transporter. Nucl Med Biol.
    1999 Jul;26(5):491-9.


Parkinson’s disease

 

  1. Prunier C., Bezard E., Montharu J., Mantzarides M., Besnard Jc., Baulieu Jl., Gros C., Guilloteau D., Chalon S.Presymptomatic diagnosis of experimental parkinsonism with 123I-PE2I SPECT. Neuroimage 2003,19:106-110.
  2. Prunier C, Payoux P, Guilloteau D, Chalon S, Giraudeau B, Majorel C, TafaniM, Bezard E, Esquerre JP, Baulieu JL. Quantification of
    dopamine transporter by 123I-PE2I SPECT and the non-invasive Logan graphical method in Parkinson's disease.J Nucl Med. 2003;44(5):663-
    70.
  3. Prunier C, Tranquart F, Cottier JP, Giraudeau B, Chalon S, Guilloteau D, De Toffol B, Chossat F, Autret A, Besnard JC, Baulieu JL.
    Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases. Nucl Med
    Commun. 2001 Nov;22(11):1207-14.


Neurodegenerative models

 

  1. Fernagut PO, Chalon S, Diguet E, Guilloteau D, Tison F, Jaber M. Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience. 2003;116(4):1123-30.
  2. Gouhier C, Chalon S, Aubert-Pouessel A, Venier-Julienne MC, Jollivet C, Benoit JP, Guilloteau D. Protection of dopaminergic nigrostriatal
    afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease. Synapse. 2002 Jun 1;44(3):124-31.
  3. Barc S, Page G, Barrier L, Garreau L, Guilloteau D, Fauconneau B, Chalon S. Relevance of different striatal markers in assessment of the
    MPP+-induced dopaminergic nigrostriatal injury in rat. J Neurochem. 2002 Feb;80(3):365-74.
  4. Gouhier C, Chalon S, Venier-Julienne MC, Bodard S, Benoit J, Besnard J,Guilloteau D. Neuroprotection of nerve growth factor-loaded
    microspheres on the D2 dopaminergic receptor positive-striatal neurones in quinolinic acid-lesioned rats: a quantitative autoradiographic
    assessment with iodobenzamide. Neurosci Lett. 2000 Jul 7;288(1):71-5.
  5. Chalon S, Emond P, Bodard S, Vilar MP, Thiercelin C, Besnard JC, GuilloteauD. Time course of changes in striatal dopamine transporters and
    D2 receptors with specific iodinated markers in a rat model of Parkinson's disease. Synapse. 1999 Feb; 31(2):134-9.


MRI Probes

 

  1. Marchand B, Douek PC, Benderbous S, Corot C, Canet E. Pilot MR evaluation of pharmacokinetics and relaxivity of specific blood pool agents for MR angiography. Invest Radiol. 2000 Jan;35(1):41-9.
  2. Kroft LJ, Doornbos J, van der Geest RJ, Benderbous S, de Roos A. Infarcted myocardium in pigs: MR imaging enhanced with slow-interstitialdiffusion
    gadolinium compound P760. Radiology. 1999 Aug;212(2):467-73.
  3. Kroft LJ, Doornbos J, Benderbous S, de Roos A. Equilibrium phase MR angiography of the aortic arch and abdominal vasculature with the
    blood pool contrast agent CMD-A2-Gd-DOTA in pigs. J Magn Reson Imaging. 1999 Jun;9(6):777-85.